Search results
Avalo Therapeutics (NASDAQ: AVTX) stock is rocketing higher on Thursday after announcing a couple of positive updates for investors in the clinical-stage biotechnology company. The first big ...
Jun 27, 2023 · Avalo (AVTX) announces that it failed to meet the primary endpoint in its mid-stage poorly controlled non-eosinophilic asthma study. The stock falls 89% on Monday following the news.
Apr 16, 2024 · Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. or. AVTX's current price target is $0.00. Learn why top analysts are making this stock forecast for Avalo Therapeutics at MarketBeat.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Aug 18, 2023 · Athersys ( ATHX) stock is tumbling on a public stock offering. The company is selling almost 11 million shares for 32 cents each. It expects to raise $3.5 million from the offering. Source ...
Apr 2, 2024 · Avalo Therapeutics AVTX is a clinical-stage biotechnology company focused on developing therapies targeting immune dysregulation. In the past week, the company’s stock has skyrocketed 269.8% ...
Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock. (GlobeNewswire) 04:01PM. Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock. (GlobeNewswire) Sep-06-21 06:43AM. Avalo Therapeutics' (NASDAQ:AVTX) investors will be pleased with their favorable 35% return over the last year.
